Syros Pharmaceuticals and Global Blood Therapeutics on Wednesday announced a research alliance to discover and develop new drugs, potentially oral medicines, to treat the inherited blood disorders sickle cell disease and beta-thalassemia.
Under the agreement, Cambridge, Mass.-based Syros scientists will use genomic analysis to identify proteins called transcription factors that turn on, or off, genes related to the production of fetal hemoglobin.
About the Author Reprints
